These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 31007050)
1. Impact of Respiratory Syncytial Virus-Confirmed Hospitalizations on Caregivers of US Preterm Infants. Pokrzywinski RM; Swett LL; Pannaraj PS; Yi J; Pavilack MS; Kumar VR; McLaurin KK Clin Pediatr (Phila); 2019 Jul; 58(8):837-850. PubMed ID: 31007050 [TBL] [Abstract][Full Text] [Related]
2. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Leidy NK; Margolis MK; Marcin JP; Flynn JA; Frankel LR; Johnson S; Langkamp D; Simoes EA Pediatrics; 2005 Jun; 115(6):1536-46. PubMed ID: 15930214 [TBL] [Abstract][Full Text] [Related]
3. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438 [TBL] [Abstract][Full Text] [Related]
4. Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons. Anderson EJ; Carbonell-Estrany X; Blanken M; Lanari M; Sheridan-Pereira M; Rodgers-Gray B; Fullarton J; Rouffiac E; Vo P; Notario G; Campbell F; Paes B Pediatr Infect Dis J; 2017 Feb; 36(2):160-167. PubMed ID: 27755464 [TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190 [TBL] [Abstract][Full Text] [Related]
6. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS). Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037 [TBL] [Abstract][Full Text] [Related]
7. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants. Krilov LR; Fergie J; Goldstein M; Brannman L Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants. DeVincenzo JP; Ambrose CS; Makari D; Weiner LB Hum Vaccin Immunother; 2016 Apr; 12(4):971-5. PubMed ID: 26889568 [TBL] [Abstract][Full Text] [Related]
9. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study. Sheridan-Pereira M; Murphy J; Sloan J; Crispino G; Leahy A; Corcoran JD; Dempsey E; Elnazir B; Gavin P; Sharif F; Gul R; Satas S; Murphy J; Gormally S; Shanaa I; Waldron D; Mc Mahon P; Carson J; Blanken M; Bont L; Paes B Pediatr Infect Dis J; 2016 Jan; 35(1):19-24. PubMed ID: 26379160 [TBL] [Abstract][Full Text] [Related]
16. Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019. Suh M; Movva N; Jiang X; Reichert H; Bylsma LC; Fryzek JP; Nelson CB J Infect Dis; 2022 Aug; 226(Suppl 2):S184-S194. PubMed ID: 35968879 [TBL] [Abstract][Full Text] [Related]
17. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States. Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376 [TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251 [TBL] [Abstract][Full Text] [Related]
19. Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy. Dovizio M; Veronesi C; Bartolini F; Cavaliere A; Grego S; Pagliaro R; Procacci C; Ubertazzo L; Bertizzolo L; Muzii B; Parisi S; Perrone V; Baraldi E; Bozzola E; Mosca F; Esposti LD Ital J Pediatr; 2024 Mar; 50(1):57. PubMed ID: 38528616 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]